The study on newly developed McAb NJ001 specific to non-small cell lung cancer and its biological characteristics.
The study on newly developed McAb NJ001 specific to non-small cell lung cancer and its biological characteristics.
复制标题
新开发的非小细胞肺癌特异性单克隆抗体NJ001及其生物学特性的研究
DOI：
10.1371/journal.pone.0033009
复制
发表时间：
2012
期刊：
影响因子：
3.7
通讯作者：
Shen H
中科院分区：
文献类型：
--
作者：
Pan S;Wang F;Huang P;Xu T;Zhang L;Xu J;Li Q;Xia W;Sun R;Huang L;Peng Y;Qin X;Shu Y;Hu Z;Shen H
单克隆抗体（McAb）是肿瘤免疫诊断和免疫治疗的重要工具。以单克隆抗体为基础的靶向肿瘤抗原的免疫治疗取得了很大的成就。本研究获得了一株持续分泌高滴度igg1型单克隆抗人非小细胞肺癌（NSCLC）细胞的细胞克隆，命名为NJ001。纯化后的NJ001滴度为2×106。NJ001特异性鉴定的NSCLC抗原SP70为相对分子质量（Mr）为70 kDa的蛋白。免疫组化染色结果显示，NJ001对非小细胞肺癌（NSCLC）有阳性反应，对人小细胞肺癌（SCLC）、肺假瘤等上皮性肿瘤的阳性或阴性反应较弱。软琼脂实验中，NJ001组菌落形成效率呈剂量依赖性下降。当浓度为100µg/ml、200µg/ml和400µg/ml时，对菌落形成的抑制率分别为23.4%、62.5%和100%。同时，与对照组相比，NJ001在肺癌异种移植模型中使肿瘤体积和肿瘤重量显著减少。200µg、400µg和800µg NJ001组肿瘤生长抑制率分别为10.44%、37.29%和44.04%。NJ001对人肺腺癌细胞SPC-A1也有明显的细胞形态学改变和诱导凋亡的作用。新开发的NJ001对NSCLC有选择性反应，在体外和体内均表现出抗肿瘤活性。NJ001在非小细胞肺癌的免疫诊断和免疫治疗方面具有重要价值，为进一步研究非小细胞肺癌肿瘤进展机制提供了前景。
Monoclonal antibody (McAb) is the key tool for cancer immunodiagnosis and immunotherapy. McAb-based immunotherapy that targets tumor antigens has had great achivement. In this study, a cell clone which kept secreting high-titer IgG1-type McAb named NJ001 against human non-small cell lung cancer (NSCLC) cells was obtained. The titer of purified NJ001 was 2×106. The antigen named SP70 of NSCLC specifically identified by NJ001 was proved to be a protein with the relative molecular mass (Mr) of 70 kDa. The results of immunohistochemical staining indicated that NJ001 could positively react to NSCLC, but weak positively or negatively react to human small-cell lung cancer (SCLC), pulmonary pseudotumor and other epithelial tumors. In soft agar assay, the colony formation efficiency in NJ001 groups decreased in a dose-dependent manner. For the concentration of 100 µg/ml, 200 µg/ml and 400 µg/ml, the inhibition ratio of colony formation was 23.4%, 62.5% and 100% respectively. Meanwhile, NJ001 caused significant reduction in tumor volume and tumor weight compared to control mice in lung cancer xenograft model. The tumor growth inhibition ratio in 200 µg, 400 µg and 800 µg NJ001 groups was 10.44%, 37.29% and 44.04%, respectively. NJ001 also led to cytomorphological changes and induced the apoptosis of human lung adenocarcinoma cell line SPC-A1 significantly. The newly developed NJ001 selectively reacted to NSCLC and exhibited anti-tumor activity both in vitro and in vivo. NJ001 is of great value concerning immunodiagnostics and immunotherapy for NSCLC and holds promise for further research regarding the mechanism underlying tumor progression of NSCLC.
登录
查看更多内容
影响因子：
5.8
作者：
Gridelli, Cesare;Maione, Paolo;Rossi, Antonio
通讯作者：
Rossi, Antonio
DOI：
10.1093/jnci/djn389
发表时间：
2008-12-03
期刊：
Journal of the National Cancer Institute
影响因子：
--
作者：
Jemal A;Thun MJ;Ries LA;Howe HL;Weir HK;Center MM;Ward E;Wu XC;Eheman C;Anderson R;Ajani UA;Kohler B;Edwards BK
通讯作者：
Edwards BK
影响因子：
3.7
作者：
Catanzaro JM;Guerriero JL;Liu J;Ullman E;Sheshadri N;Chen JJ;Zong WX
通讯作者：
Zong WX
影响因子：
5.7
作者：
Pal SK;Figlin RA;Reckamp K
通讯作者：
Reckamp K
影响因子：
46.9
作者：
Reichert, JM;Rosensweig, CJ;Dewitz, MC
通讯作者：
Dewitz, MC